Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Radiopharm Theranostics
Deal Size : $4.0 million
Deal Type : Acquisition
Details : Pharma15 is developing assets which seek to overcome resistance to prostate-specific membrane antigen (PSMA) targeting cancer therapies currently available or in late-stage development.
Brand Name : Undisclosed
Molecule Type : Large molecule
Upfront Cash : $2.0 million
March 03, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Radiopharm Theranostics
Deal Size : $4.0 million
Deal Type : Acquisition
LOOKING FOR A SUPPLIER?